World Wires · story 5211 · unverified · 1 source(s)

Invivyd reports positive Phase 3 results for VYD2311 antibody

Invivyd announced positive topline Phase 3 trial data demonstrating that its COVID-19 monoclonal antibody candidate VYD2311 has safety and tolerability sup

Open in the desk

Coverage

• Invivyd reports positive Phase 3 results for VYD2311 antibody GlobeNewswire: public companies · tier D · clear net · 2026-09-29 11:01 UTC

What this site indexes